<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431414</url>
  </required_header>
  <id_info>
    <org_study_id>CoVPN 5001</org_study_id>
    <secondary_id>5UM1AI068614-14</secondary_id>
    <nct_id>NCT04431414</nct_id>
  </id_info>
  <brief_title>A Study of Immune Responses to the Virus That Causes COVID-19</brief_title>
  <acronym>CoVPN 5001</acronym>
  <official_title>A Prospective Study of Acute Immune Responses to SARSCoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COVID-19 Prevention Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>COVID-19 Prevention Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about the acute response to infection with and&#xD;
      recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).&#xD;
      Some people know this virus by the name &quot;coronavirus.&quot; It can cause the disease called&#xD;
      COVID-19.&#xD;
&#xD;
      The information gained from the study can be used to help develop better tests for SARS-CoV-2&#xD;
      infection and COVID-19 disease and may help in developing future vaccines, other prevention&#xD;
      strategies, and treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study of acute immune responses to SARSCoV-2 infection.&#xD;
&#xD;
      The study will include 3 groups, as described in the table below. Groups are defined based on&#xD;
      clinical status at enrollment, but for the purposes of data analysis, participants who&#xD;
      experience disease progression can contribute data to other cohorts.&#xD;
&#xD;
      Participants will complete six visits over 28 days followed by a health contact at Month 2&#xD;
      (one month after the last scheduled visit). Additional follow up visit(s) may be added over&#xD;
      time in response to evolving information regarding SARS-CoV-2 infection and COVID-19.&#xD;
&#xD;
      Study visits may include review of medical history; interviews/questionnaires; pregnancy&#xD;
      tests (for participants assigned female sex at birth); blood draws; nasal swab, nasal wash,&#xD;
      and saliva sample collection; and optional stool sample collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">October 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of SARS-CoV-2-specific B cells in peripheral blood samples</measure>
    <time_frame>Measured through day 14</time_frame>
    <description>Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of SARS-CoV-2-specific B cells in peripheral blood samples</measure>
    <time_frame>Measured through day 14</time_frame>
    <description>Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phenotypic characterization of SARS-CoV-2-specific B cells in peripheral blood samples</measure>
    <time_frame>Measured through day 14</time_frame>
    <description>Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate of SARS-CoV-2-specific antibody binding in serum samples</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by binding antibody multiplex assay (BAMA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by neutralizing antibody assay (nAb)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of SARS-CoV-2-specific antibody binding antibodies in serum samples</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by binding antibody multiplex assay (BAMA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of SARS-CoV-2-specific neutralizing antibodies in serum samples</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by neutralizing antibody assay (nAb)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate of SARS-CoV-2-specific binding antibodies in nasal wash samples</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by binding antibody multiplex assay (BAMA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of SARS-CoV-2-specific binding antibodies in nasal wash samples</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by binding antibody multiplex assay (BAMA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of leukocyte populations in peripheral blood</measure>
    <time_frame>Measured through day 14</time_frame>
    <description>Measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcriptional profiles of peripheral blood leukocytes</measure>
    <time_frame>Measured through day 14</time_frame>
    <description>Measured by gene expression analysis by RNA sequencing, real-time PCR, single-cell proteogenomic profiling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of serum cytokines and other soluble factors</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by multiplexed protein detection assays and/or enzyme-linked immunosorbent assays (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of SARS-CoV-2-specific CD4+ and CD8+ T cells</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional profiling, including intracellular cytokine staining, of SARS-CoV-2-specific CD4+ and CD8+ T cells</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitation of viral RNA in nasal swabs</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Measured by extraction of nucleic acid for analysis of microorganism RNA or DNA by qPCR and/or amplicon- or metagenomics-sequencing methods and subsequent gene and taxa-level bioinformatics analyses</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Persons that are positive for SARS-CoV-2 and are asymptomatic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Persons that are positive for SARS-CoV-2 with recent onset of mild symptoms (not hospitalized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Persons that are positive for SARS-CoV-2 and are symptomatic hospitalized patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>blood, nasal swab, nasal wash, and saliva&#xD;
optional stool swab</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who have tested positive for SARSCoV-2 virus by RT-PCR or antigen testing.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
          -  Test result indicating presence of SARS-CoV-2 virus. Sites must have results from&#xD;
             assays that are approved as FDA-emergency use authorized or as standard-of-care by&#xD;
             other applicable regional governing bodies. For timing of testing, please see group&#xD;
             specific criteria below.&#xD;
&#xD;
          -  Ability and willingness to provide informed consent.&#xD;
&#xD;
          -  Willingness to have clinical research staff come to place of residence or hospital if&#xD;
             needed.&#xD;
&#xD;
          -  Willingness to be followed for the planned duration of the study.&#xD;
&#xD;
          -  Assessment of understanding: volunteer demonstrates understanding of this study.&#xD;
&#xD;
          -  Agreement to allow access to medical records.&#xD;
&#xD;
          -  Asymptomatic participants:&#xD;
&#xD;
               -  No current symptoms.&#xD;
&#xD;
               -  No symptoms consistent with COVID-19 within 2 weeks prior to positive test&#xD;
                  according to the clinical judgement of the investigating clinician. Symptoms&#xD;
                  include, but are not limited to, fever, headache, sore throat, cough, dyspnea,&#xD;
                  rhinorrhea, diarrhea, myalgias, chills, and anosmia. Please refer to&#xD;
                  https://www.cdc.gov/coronavirus/2019-ncov/symptomstesting/symptoms.html for the&#xD;
                  current list of symptoms consistent with COVID-19.&#xD;
&#xD;
               -  Positive SARS-CoV-2 RNA test or antigen test within six days prior to enrollment&#xD;
                  (target time) up to 10 days prior to enrollment (upper allowable window).&#xD;
&#xD;
          -  Symptomatic (non-hospitalized) participants:&#xD;
&#xD;
               -  Onset of mild symptoms consistent with COVID-19 within 6 days prior to enrollment&#xD;
                  (target time) up to 14 days prior to enrollment (upper allowable window).&#xD;
                  Symptoms of COVID-19 to be determined by the clinical judgement of the&#xD;
                  investigating clinician including-- but not limited to-- fever, headache, sore&#xD;
                  throat, cough, dyspnea, rhinorrhea, diarrhea myalgias, chills, and anosmia.&#xD;
                  Please refer to&#xD;
                  https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html for the&#xD;
                  current list of symptoms consistent with COVID-19.&#xD;
&#xD;
               -  Positive SARS-CoV-2 RNA test or antigen test within six days prior to enrollment&#xD;
                  (target time) up to 10 days prior to enrollment (upper allowable window).&#xD;
&#xD;
          -  Symptomatic (hospitalized) participants&#xD;
&#xD;
               -  Participant hospitalized for COVID-19 within 3 days prior to enrollment (note:&#xD;
                  there is no timeframe for either symptom onset or timing of SARS-CoV-2 PCR or&#xD;
                  antigen testing for hospitalized participants)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or other condition that, in the judgment of&#xD;
             the investigator, would interfere with, or serve as a contraindication to, protocol&#xD;
             adherence or a volunteer's ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Will Hahn</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy Ward</last_name>
    <role>Study Chair</role>
    <affiliation>Cape Town - Khayelitsha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridge HIV CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hope Clinic of the Emory Vaccine Center CRS</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Adolescent Trials Unit CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Vaccine CRS (BWH VCRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Blood Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Prevention CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Vaccine and Prevention CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Huesped CRS</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos JM Ramos Mejía CRS</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaborone CRS</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOM Federal University Minas Gerais Brazil NICHD CRS</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malawi CRS</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merida CRS</name>
      <address>
        <city>Mérida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS</name>
      <address>
        <city>Bellavista</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociacion Civil Selva Amazonica (ASCA) CRS</name>
      <address>
        <city>Iquitos</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barranco CRS</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Miguel CRS</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur HIV CRS</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khayelitsha CRS / (CIDRI UCT)</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masiphumelele Clinical Research Site (MASI) CRS</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatsworth CRS</name>
      <address>
        <city>Chatsworth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Botha's Hill CRS</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAPRISA eThekwini CRS</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vulindlela CRS</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ndlovu Research Centre CoVPN CRS</name>
      <address>
        <city>Elandsdoorn</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isipingo CRS</name>
      <address>
        <city>Isipingo</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliptown Soweto CRS</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto HVTN CRS</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurum Institute Klerksdorp CRS</name>
      <address>
        <city>Klerksdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo Research Clinic CRS</name>
      <address>
        <city>Ladysmith</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MeCRU CRS</name>
      <address>
        <city>Medunsa</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson Mandela Academic Research Unit CRS</name>
      <address>
        <city>Mthatha</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rustenburg CRS</name>
      <address>
        <city>Rustenburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre CRS</name>
      <address>
        <city>Soshanguve</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tembisa Clinic 4 CoVPN CRS</name>
      <address>
        <city>Tembisa</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongaat CRS</name>
      <address>
        <city>Tongaat</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS</name>
      <address>
        <city>Mbeya</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matero Reference Clinic CRS</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambia Emory HIV Research Project - Lusaka CoVPN CRS</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambia Emory HIV Research Project - Ndola CoVPN CRS</name>
      <address>
        <city>Ndola</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton Park CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke South CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Botswana</country>
    <country>Brazil</country>
    <country>Malawi</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>United States</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Kenya</country>
    <country>Mozambique</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

